Journal article
Association of high-sensitivity C-reactive protein with de novo major depression
Julie A Pasco, Geoffrey C Nicholson, Lana J Williams, Felice N Jacka, Margaret J Henry, Mark A Kotowicz, Hans G Schneider, Brian E Leonard, Michael Berk
British Journal of Psychiatry | ROYAL COLLEGE OF PSYCHIATRISTS | Published : 2010
Abstract
BACKGROUND: Although there is cross-sectional evidence that changes in the immune system contribute to the pathophysiology of depression, longitudinal data capable of elucidating cause and effect relationships are lacking. AIMS: We aimed to determine whether subclinical systemic inflammation, as measured by serum high-sensitivity C-reactive protein (hsCRP) concentration, is associated with an increased risk of de novo major depressive disorder. METHOD: Major depressive disorder was diagnosed using a clinical interview (SCID-I/NP). This is a retrospective cohort study; from a population-based sample of 1494 randomly selected women recruited at baseline during the period 1994-7, 822 were follo..
View full abstractGrants
Funding Acknowledgements
M.B. has received grant/research support from the Stanley Medical Research Foundation, MBF, National Health and Medical Research Council, Beyond Blue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier and AstraZeneca. He has been a paid consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Pfizer, and a paid speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth.The study was funded by the Victorian Health Promotion Foundation and the National Health and Medical Research Council of Australia.